News
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo from company Gilead Sciences, remained ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...
June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent ...
Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results